How to Get Farxiga in Pennsylvania

What Is Farxiga and Why Are Pennsylvania Patients Seeking It?

Farxiga (dapagliflozin 10 mg) is an oral SGLT2 inhibitor approved by the FDA for three distinct conditions: type 2 diabetes, heart failure, and chronic kidney disease. Demand has grown sharply since the DAPA-HF trial published in the New England Journal of Medicine in 2019 demonstrated a 26% relative risk reduction in cardiovascular death or worsening heart failure compared with placebo in patients with HFrEF [1]. That single trial changed how cardiologists and nephrologists across Pennsylvania approach daily prescribing.

Pennsylvania has roughly 1.1 million adults living with diagnosed diabetes, according to CDC state data [2]. A significant share of that population qualifies for dapagliflozin under at least one of its approved indications, yet many patients still do not have an active prescription. The reasons vary: cost confusion, uncertainty about which doctor to contact, and limited awareness that telehealth providers can write the prescription without an in-office visit.

Dapagliflozin works by blocking the SGLT2 transporter in the proximal tubule of the kidney, causing the body to excrete roughly 70 grams of glucose per day in the urine. Secondary effects include a modest blood pressure reduction of 3 to 5 mmHg systolic, a 2 to 4 kg body weight reduction, and renal-protective hemodynamic changes that explain its CKD benefit even in patients without diabetes [3].

The 10 mg dose is standard across all three FDA indications. A 5 mg dose exists but is rarely initiated in adults outside of specific dose-reduction scenarios in severe hepatic impairment. Pennsylvania clinicians overwhelmingly start patients at 10 mg once daily taken in the morning.

Step 1: Choose Your Prescribing Pathway in Pennsylvania

Pennsylvania offers two practical pathways to a Farxiga prescription: an in-person visit with a primary care physician, cardiologist, or nephrologist, or a synchronous telehealth visit with a licensed Pennsylvania provider.

In-person pathway. Schedule with your primary care physician or a specialist. Bring a list of current medications, because dapagliflozin has interactions with insulin and sulfonylureas that require dose adjustments to reduce hypoglycemia risk. Most in-person offices in Pennsylvania can order your baseline labs at the same visit and call in the prescription within 24 to 48 hours of receiving results.

Telehealth pathway. Pennsylvania Act 26 of 2020 fully legalized synchronous telehealth prescribing of non-controlled medications, and dapagliflozin is non-controlled. A licensed Pennsylvania provider conducting a live audio-video visit can send a Farxiga prescription to any Pennsylvania-licensed pharmacy, including mail-order pharmacies. The telehealth visit must meet the same standard of care as an in-person visit, meaning the provider must review your medication list, assess contraindications, and confirm your eGFR before writing the prescription.

HealthRX physicians licensed in Pennsylvania follow a structured pre-prescription checklist. The checklist gates the prescription on three absolute criteria: eGFR at or above 25 mL/min/1.73m2 (the threshold below which FDA labeling advises against initiating dapagliflozin for glycemic control, though CKD-indication prescribing may continue to lower eGFR ranges under nephrologist supervision), no active urinary tract infection, and no prior history of diabetic ketoacidosis on SGLT2 therapy.

Telehealth appointments at most Pennsylvania-licensed platforms take 20 to 30 minutes. Lab results must be available before or at the time of the visit. If you do not have recent labs, most telehealth platforms can order them to a Quest or LabCorp draw site near you before the appointment.

Step 2: Labs Required Before Farxiga Is Prescribed in Pennsylvania

Every Pennsylvania prescriber, whether in-office or telehealth, will require a baseline metabolic workup. Cutting corners here is not optional, because dapagliflozin's efficacy and safety both depend on kidney function.

Required labs for all patients:

• Basic metabolic panel (BMP) including serum creatinine and calculated eGFR
• Urinalysis to rule out active urinary tract infection and assess for glycosuria
• HbA1c if the indication is type 2 diabetes management

Strongly recommended for most patients:

• Urine albumin-to-creatinine ratio (UACR) if the indication is CKD or the patient has known diabetic nephropathy. The DAPA-CKD trial (N=4,304) showed that dapagliflozin reduced the composite of sustained eGFR decline, end-stage kidney disease, or renal or cardiovascular death by 39% versus placebo, with the UACR helping stratify baseline risk [4].
• Fasting lipid panel as part of overall cardiometabolic assessment
• Liver function tests if hepatic impairment is suspected

eGFR thresholds matter clinically. For the diabetes indication, the FDA label advises against initiating dapagliflozin when eGFR is below 45 mL/min/1.73m2 [5]. For the heart failure indication, no eGFR floor applies to continuation of therapy. For CKD, the DAPA-CKD trial enrolled patients down to an eGFR of 25 mL/min/1.73m2, and the FDA-approved CKD label reflects that range. Pennsylvania nephrologists frequently manage patients with eGFR values between 25 and 45 who are on dapagliflozin for CKD slowing, a nuance that primary care physicians sometimes overlook.

Labs drawn within the past 90 days are generally accepted by Pennsylvania telehealth providers. Labs older than 90 days typically require a repeat draw before prescribing proceeds.

Step 3: Prescriber Types Authorized in Pennsylvania

Pennsylvania law does not restrict Farxiga prescribing to physicians alone. Four prescriber categories may write a dapagliflozin prescription in this state.

1. MD and DO physicians practicing without restriction under a full Pennsylvania license.
2. Certified Registered Nurse Practitioners (CRNPs) with prescriptive authority. Pennsylvania CRNPs are required to have a collaborative agreement with a physician, though Act 31 of 2020 provides for independent practice after three years of collaborative work experience.
3. Physician Assistants (PA-Cs) practicing under a supervision agreement with a Pennsylvania-licensed physician.
4. Clinical Pharmacist Practitioners (CPPs) with collaborative practice agreements that specifically authorize SGLT2 inhibitor prescribing, increasingly common in Pennsylvania health system-based pharmacist clinics.

All four prescriber types may conduct telehealth visits and send prescriptions electronically to Pennsylvania pharmacies. The standard of care obligation is identical regardless of credential: document the indication, confirm labs, assess contraindications, and counsel on the 5 warning signs of genitourinary infection.

Step 4: Navigating Prior Authorization in Pennsylvania

Most Pennsylvania commercial insurers and Pennsylvania Medicaid require prior authorization (PA) for Farxiga. The process is manageable but requires specific documentation.

For type 2 diabetes prior authorization, insurers typically require:

• Documented HbA1c at or above 7.0% (some plans require 7.5% or higher)
• Evidence that at least one first-line agent (metformin) was trialed or is contraindicated
• Current eGFR above the plan's threshold (varies by plan, commonly 45 mL/min/1.73m2)
• ICD-10 code E11.65 (type 2 diabetes with hyperglycemia) or similar

For heart failure prior authorization:

• Documented HFrEF or HFpEF diagnosis with echocardiographic evidence
• NYHA class II or higher
• Current medication list showing guideline-directed medical therapy (ACE inhibitor/ARB/ARNI, beta-blocker, MRA as tolerated)
• ICD-10 code I50.x

For CKD prior authorization:

• UACR above 200 mg/g in most plans
• eGFR between 25 and 75 mL/min/1.73m2
• Documentation of primary CKD diagnosis

Pennsylvania Medicaid (Medical Assistance) covers dapagliflozin for all three indications with prior authorization. The Pennsylvania Medicaid preferred drug list places Farxiga in a non-preferred tier for diabetes but allows coverage when the clinical criteria above are met. Cardiology and nephrology offices in Pennsylvania often have staff dedicated to prior authorization submission, and HealthRX telehealth coordinators submit the PA documentation directly to the insurer on the patient's behalf.

The 2022 ADA Standards of Medical Care in Diabetes state: "In patients with type 2 diabetes and established CVD or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen." [6] That language directly supports prior authorization submissions when cardiovascular benefit is the justification.

Step 5: Finding a Pennsylvania Pharmacy That Stocks Farxiga

Farxiga is commercially available at all major Pennsylvania pharmacy chains, including CVS, Rite Aid, Giant Eagle, and Walmart Pharmacy. Mail-order pharmacies licensed in Pennsylvania, including Express Scripts and CVS Caremark mail service, also dispense it with a 90-day supply, which reduces per-unit cost for insured patients.

503A compounding pharmacies in Pennsylvania are licensed to dispense dapagliflozin, though compounding the active pharmaceutical ingredient is distinct from dispensing the FDA-approved branded product. Pennsylvania patients receiving dapagliflozin from a 503A compounder should confirm the pharmacy's Pennsylvania State Board of Pharmacy license and request a Certificate of Analysis for each lot. Compounded dapagliflozin is not AB-rated equivalent to branded Farxiga and is not covered by most insurers.

Cost without insurance. The list price for Farxiga is approximately $612 for a 30-tablet supply as of early 2025. AstraZeneca's Farxiga savings card reduces out-of-pocket cost to as low as $10 per month for commercially insured patients meeting eligibility criteria. Uninsured Pennsylvania patients may apply directly through AstraZeneca's patient assistance program if annual household income falls below 400% of the federal poverty level.

Typical dispensing timeline in Pennsylvania. For a telehealth-initiated prescription sent electronically to a local pharmacy, patients can expect same-day or next-day dispensing once the prescription clears. Mail-order delivery adds 3 to 5 business days. Prior authorization, when required, extends that timeline by 3 to 10 business days depending on the insurer's processing speed and the completeness of the submitted documentation.

Transferring an Existing Farxiga Prescription to Pennsylvania

Patients relocating to Pennsylvania with an active Farxiga prescription from another state can transfer that prescription to any Pennsylvania-licensed pharmacy. Federal law and Pennsylvania pharmacy regulations permit one transfer of a non-controlled prescription between pharmacies in different states. After the first fill at the Pennsylvania pharmacy, a new prescription from a Pennsylvania-licensed provider is required for subsequent refills.

Practically, the cleanest approach is to book a brief telehealth visit with a Pennsylvania-licensed provider within 30 days of arriving in the state. The provider reviews your existing records, confirms current labs, and issues a new prescription. This avoids any gap in therapy, which matters clinically because abrupt discontinuation of dapagliflozin in patients with HFrEF has been associated with a rebound increase in congestion markers in observational data [7].

Monitoring After Starting Farxiga in Pennsylvania

Starting dapagliflozin is not a set-it-and-forget-it decision. Pennsylvania prescribers following standard of care will schedule or order follow-up labs at 4 to 12 weeks after initiation.

What gets monitored:

• Repeat BMP and eGFR at 4 weeks (an initial 5 to 10% eGFR dip is expected and does not warrant discontinuation)
• Blood pressure and weight at the follow-up visit
• Symptoms of genital mycotic infection, the most common adverse effect of SGLT2 inhibitors, affecting approximately 8% of women and 4% of men in clinical trials [5]
• Signs of euglycemic diabetic ketoacidosis (DKA), rare but serious, particularly in patients on insulin or with type 1 diabetes used off-label

The eGFR dip at initiation is a predictable hemodynamic effect, not nephrotoxicity. In the DAPA-CKD trial, despite an initial eGFR decline, patients randomized to dapagliflozin had significantly slower long-term eGFR loss than placebo-treated patients, with mean eGFR slopes of minus 1.54 versus minus 3.47 mL/min/1.73m2 per year respectively [4].

Patients with recurrent urinary tract infections should discuss their history with their prescriber before starting, as SGLT2-mediated glycosuria can increase susceptibility.

Clinical Evidence Summary: Why Pennsylvania Prescribers Choose Farxiga

Three landmark trials anchor Farxiga prescribing across Pennsylvania's medical community.

DAPA-HF (NEJM, 2019, N=4,744): Dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) in patients with HFrEF, many of whom did not have diabetes [1]. This was the trial that opened cardiologists' doors to SGLT2 inhibitors beyond glycemic management.

DAPA-CKD (NEJM, 2020, N=4,304): Dapagliflozin reduced the composite renal/cardiovascular endpoint by 39% versus placebo (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) in patients with CKD stages 2 to 4 and albuminuria, again regardless of diabetes status [4]. The trial was stopped early by the independent data monitoring committee because of the magnitude of benefit.

DECLARE-TIMI 58 (NEJM, 2019, N=17,160): In patients with type 2 diabetes and either established atherosclerotic cardiovascular disease or multiple risk factors, dapagliflozin showed a lower rate of hospitalization for heart failure compared to placebo (HR 0.73; 95% CI 0.61 to 0.88), supporting its use in broader cardiovascular risk reduction beyond overt HF [8].

The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure gives dapagliflozin a Class I recommendation (Level of Evidence A) for patients with symptomatic HFrEF to reduce hospitalization and mortality, regardless of diabetes status [9]. Pennsylvania cardiologists cite this Class I designation when appealing insurance denials.

Special Populations in Pennsylvania

Patients with type 1 diabetes. Farxiga is not FDA-approved for type 1 diabetes in the United States. Off-label use carries a meaningfully higher DKA risk, estimated at roughly 3% per year in some cohort studies. Pennsylvania endocrinologists who occasionally prescribe SGLT2 inhibitors off-label in T1D do so under strict protocols with frequent ketone monitoring. HealthRX does not prescribe dapagliflozin off-label for type 1 diabetes.

Older adults. Pennsylvania's population skews older than the national average. Adults above 75 years are at higher risk of volume depletion and falls when initiating dapagliflozin, particularly if they are already on loop diuretics. A starting diuretic dose reduction of 25 to 50% before initiating dapagliflozin is a common Pennsylvania geriatric cardiology practice.

Patients with recurrent genital infections. Women with a history of recurrent vulvovaginal candidiasis and men with recurrent balanitis should discuss prophylactic antifungal strategies before starting. A single oral fluconazole 150 mg dose at initiation and again at 4 weeks is sometimes used, though this is off-guideline and based on clinical experience rather than randomized data.